Vir Biotechnology Inc
NASDAQ:VIR

Watchlist Manager
Vir Biotechnology Inc Logo
Vir Biotechnology Inc
NASDAQ:VIR
Watchlist
Price: 7.12 USD 2.45% Market Closed
Market Cap: 980.6m USD
Have any thoughts about
Vir Biotechnology Inc?
Write Note

Vir Biotechnology Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vir Biotechnology Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Vir Biotechnology Inc
NASDAQ:VIR
Depreciation & Amortization
-$500k
CAGR 3-Years
21%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vir Biotechnology Inc
Glance View

Market Cap
973.3m USD
Industry
Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 444 full-time employees. The company went IPO on 2019-10-11. The company has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The firm's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. The company is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.

VIR Intrinsic Value
1.74 USD
Overvaluation 75%
Intrinsic Value
Price

See Also

What is Vir Biotechnology Inc's Depreciation & Amortization?
Depreciation & Amortization
-500k USD

Based on the financial report for Dec 31, 2023, Vir Biotechnology Inc's Depreciation & Amortization amounts to -500k USD.

What is Vir Biotechnology Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
15%

Over the last year, the Depreciation & Amortization growth was 0%. The average annual Depreciation & Amortization growth rates for Vir Biotechnology Inc have been 21% over the past three years , 15% over the past five years .

Back to Top